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Triad3a induces the degradation of early
necrosome to limit RipK1-dependent
cytokine production and necroptosis
Norah A. Alturki1,2, Scott McComb3, Ardeshir Ariana1, Dikchha Rijal1, Robert G. Korneluk1,4, Shao-Cong Sun5,
Emad Alnemri6 and Subash Sad1,7
Abstract
Understanding the molecular signaling in programmed cell death is vital to a practical understanding of inﬂammation
and immune cell function. Here we identify a previously unrecognized mechanism that functions to downregulate the
necrosome, a central signaling complex involved in inﬂammation and necroptosis. We show that RipK1 associates with
RipK3 in an early necrosome, independent of RipK3 phosphorylation and MLKL-induced necroptotic death. We ﬁnd
that formation of the early necrosome activates K48-ubiquitin-dependent proteasomal degradation of RipK1, Caspase-
8, and other necrosomal proteins. Our results reveal that the E3-ubiquitin ligase Triad3a promotes this negative
feedback loop independently of typical RipK1 ubiquitin editing enzymes, cIAPs, A20, or CYLD. Finally, we show that
Triad3a-dependent necrosomal degradation limits necroptosis and production of inﬂammatory cytokines. These
results reveal a new mechanism of shutting off necrosome signaling and may pave the way to new strategies for
therapeutic manipulation of inﬂammatory responses.
Introduction
Macrophage-like cells are present throughout the body
and play a major role in initiating inﬂammatory responses
to control pathogens1–4. TLR signaling induces MyD88-
dependent and TRIF-dependent signaling, which leads to
the production of cytokines and chemokines5–8, and
recruitment of myeloid cells9.
Apoptosis promotes cell death during embryogenesis
and in the elimination of self-reactive cells10,11. Cell death
that occurs during infections proceeds through parallel
cell death programs12. In contrast to apoptosis, inﬂam-
matory cell death results in cell-rupture and release of
intracellular contents including cytokines and numerous
danger-associated molecular patterns (DAMPs) to the
external milieu, which induces systemic ampliﬁcation of
inﬂammation10,13,14. Inﬂammatory cell death by patho-
gens is now considered to be a key driver of pathogen
virulence15–19.
While necrosis was once considered to be an accidental,
uncontrolled mode of inﬂammatory cell death, a pathway
of regulated necrosis, called “necroptosis” is now known
to be induced by TNF-R or IFN-IR engagement14,17,20–25.
Necrosome signaling involves RipK1–FADD–Caspase-8
interaction, which leads to the phosphorylation of
RipK326–28. Activated RipK3 phosphorylates mixed line-
age kinase domain-like protein (MLKL), resulting in tri-
merization of MLKL and its relocation to the cell
membrane, causing membrane rupture and necroptosis29.
We have revealed a novel mechanism of proteasomal
degradation of RipK1 and other interacting proteins by
Triad3a. Our results indicate that during early necrosome
signaling, Triad3a mediates the degradation of RipK3
interacting proteins to regulate necroptosis and expres-
sion of inﬂammatory cytokines.
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Results
Necrosome activation leads to the degradation of various
interacting proteins
Combined TLR4 stimulation (by LPS) and caspase
inhibition (by zVAD) in macrophages causes the phos-
phorylation of RipK1 and RipK3, which can be observed
as a slightly slower migrating protein band in western
blot. Consistent with this, RipK1 and RipK3 were resolved
as a single band upon dephosphorylation by calf intestinal
phosphatase (CIP) (Fig. 1a). Coincident with phosphor-
ylation of RipK3, we noted a progressive reduction in the
levels of RipK1 after 2 h post stimulation (Fig. 1a).
Treatment of macrophages with zVAD in the absence of
any additional stimulation did not induce the phosphor-
ylation of RipK1 or RipK3, and failed to have any impact
on the levels of RipK1 (Fig. 1b). Stimulation of cells with
LPS in the absence of zVAD, induced the phosphorylation
of RipK1, but not RipK3, without having any impact on
the levels of RipK1 (Fig. 1c). Thus, consistent with pre-
vious results30, combined LPS and zVAD was required for
the phosphorylation of RipK3 that correlated with pro-
gressive disappearance of RipK1 and eventual cell death
by necroptosis (Fig. 1c–e and Fig. S1 A, B). We also
measured the expression of protein phosphatase-2, B
subunit, a ubiquitous phosphatase in eukaryotic cells, and
observed that this protein is also not degraded necrosome
signaling (Fig. S1 C). Progressive loss of RipK1 was also
observed when cells were stimulated with zVAD in the
presence of highly reduced amount of LPS (Fig. S1 D).
Reduction in the levels of RipK1 following necroptotic
stimulus was not due to poor transcription of RipK1 as
measured by qRT-PCR (Fig. 1f).
Although the reduction in RipK1 levels correlated with
phosphorylation of RipK3 (Fig. 1d), the relative levels of
RipK3 did not diminish during early necrosome signaling,
and no cleavage bands of RipK1 or RipK3 were observed
(Fig. S1 A, B). Loss of RipK1 was also noted when
necroptosis was induced with TNFα+ zVAD (Fig. 1g–i),
and again correlated with the timing of RipK3 phos-
phorylation (Fig. 1g, h). Many other components of the
necrosome were degraded following LPS+ zVAD stimu-
lation, including Caspase-8 (Casp-8), FADD, TRAF2, and
cIAP-1 and -2 (Fig. 1j, k). In contrast, there was an
increase in the expression of RipK3, CYLD, and A20
following stimulation of cells with LPS+ zVAD (Fig. 1j,
k), indicating that all proteins are not degraded during
necrosome signaling.
Reduction in the levels of Casp-8 following necrop-
totic stimulus was not due to poor transcription of
Casp-8 (Fig. S1 E). Substitution of the pan-caspase
inhibitor (zVAD) with the Casp-8 inhibitor (zIETD)
failed to induce the loss of RipK1 expression or
necroptosis of macrophages (Fig. S1 F, G). While Casp-8
inhibitor reduced the Casp-8 activity to baseline levels
(Fig. S1 H), it did not rescue the loss of RipK1 expres-
sion following stimulation by LPS+ zVAD (Fig. S1 I).
This suggests that the loss of RipK1 expression is not
due to cleavage of RipK1 by Casp-8. Furthermore, Casp-
8 itself was degraded (Fig. 1j).
Necrosomal degradation is driven by RipK3
The canonical kinase function of RipK1 is mediated by
the catalytic triad that comprises K45-E63-D15631. The
two critical kinase regions, K45 and D138 complement
each other in driving necrosome signaling and inﬂam-
matory responses32,33. We next tested whether the K45
kinase region of RipK1, which has been shown to promote
necroptosis under some conditions19, was required for the
degradation of RipK1. K45A mutation of RipK1 resulted
in slightly reduced RipK3 phosphorylation and necrop-
tosis but failed to have any signiﬁcant impact on the
degradation of RipK1 (Fig. 2a, b). In contrast, the degra-
dation of RipK1 and necroptosis was dependent on the
K45 region of RipK1 when cells were stimulated with
TNFα+ zVAD (Fig. S2 A, B). Following LPS/zVAD-
induced necroptosis, the reduction in the levels of RipK1,
Casp-8, cIAP1,2, and FADD was dependent on TRIF, but
not on Myd88 signaling (Fig. 2c, d), whereas for TNFα+
zVAD stimulation, degradation of RipK1 and necroptosis
were not dependent on TRIF (Fig. S2 C, D). Overall, we
observed a strong correlation between RipK1 degradation,
RipK3 phosphorylation, and eventual progression to
necroptotic cell death, and a signiﬁcant difference in the
mechanism of RipK1 degradation following TNF-α- or
LPS-induced necrosome signaling.
RipK3-deﬁcient cells were protected against necroptosis
and there was no degradation of RipK1, cIAP1/2, and
Caspase-8 (Fig. 2e, f and Fig. S2 E). In contrast, when cells
were stimulated with LPS only, which does not induced
necroptosis, RipK3 did not have any impact on the
expression of RipK1, cIAP1/2, and Casp-8 (Fig. S2 F). We
wondered about a possible role for the downstream
mediator of necroptotic cell death, MLKL29. Degradation
of RipK1 and Casp-8 was not inhibited in MLKL-deﬁcient
macrophages (Fig. 2g and Fig. S2 G). As expected, MLKL-
deﬁcient macrophages were resistant to necroptotic cell
death (Fig. 2f). We evaluated the expression of these
proteins in Irf9−/− and Ifnar1−/− macrophages that are
resistant to necroptosis30. Our results indicate that the
degradation of these proteins was not modulated in Irf9−/
− and Ifnar1−/− macrophages (Fig. S2 H, I), suggesting
that degradation continues during necrosome signaling in
the absence of cell death. Loss of MLKL led to a sig-
niﬁcant decrease in RipK3 phosphorylation, suggesting
the presence of a feedback role for MLKL in RipK3
phosphorylation (Fig. 2g). RipK3 was also required for
necroptosis and the degradation of RipK1 following sti-
mulation of cells with TNFα+ zVAD (Fig. 2h, i). Thus,
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RipK3, but not MLKL is required for necrosomal degra-
dation in macrophages following necroptotic stimulus.
Necrosomal degradation is driven by early RipK1–RipK3
interaction
Nec-1 has been shown to bind the kinase domain of
RipK1 between the N- and C-lobes near the activation
loop34, and lock RipK1 in an inactive conformation34.
Nec-1 completely abrogated the phosphorylation of
RipK3, degradation of RipK1 and cell death by necroptosis
(Fig. 3a, c, d). Similar results were obtained with Nec-1S
(Fig. S3 A, B), a more speciﬁc inhibitor of RipK135. Nec-1
had no impact on the phosphorylation of RipK1 (Fig. 3a).
Inhibition of the p38MAPK resulted in potent inhibition
of RipK1 phosphorylation but had no impact on the
reduction of RipK1 levels (Fig. S3 C). Despite an obvious
Fig. 1 Necrosome signaling leads to degradation of necrosome interacting proteins. a Bone marrow-derived macrophages were treated with
LPS (100 ng/ml) and zVAD (50 μM). Lysates were collected at various time intervals and examined by western blotting. Phosphatase (CIP, 50 units)
was added to some lysates as described in the Methods section. b, c Macrophages were cultured with zVAD, LPS, or with LPS+ zVAD as indicated.
Lysates were tested by western blotting. d Densitometry analysis of total RipK1 vs. phosphorylated RipK3 in cells treated with LPS+ zVAD at various
time intervals. e Cell viability was measured by MTT assay at 24 h post stimulation of cells with LPS+ zVAD. f The expression of RipK1 mRNA was
examined by quantitative RT-PCR at 6 h post stimulation with LPS+ zVAD in comparison to untreated controls. g Bone marrow-derived
macrophages were treated with TNFα (10 ng/ml) and zVAD (50 μM), and lysates were collected at various time intervals and examined by western
blotting. h Densitometry analysis of total RipK1 vs. phosphorylated RipK3 in cells treated with TNFα+ zVAD at various time intervals. i Cell death of
macrophages treated with TNFα or TNFα+ zVAD was measured by MTT assay at 24 h post stimulation. j Macrophages were treated with LPS+ zVAD
and the expression of various proteins was evaluated by western blotting of cell extracts collected at various time intervals. k Densitometric analysis
of proteins shown in panel (j) was performed. Graphs show the percentage of viable cells ±SEM relative to controls. Each experiment was performed
in triplicate and repeated three times. ****P < 0.0001
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decrease in RipK1 phosphorylation by p38MAPK inhibi-
tion, this did not affect RipK1 degradation, and resulted in
only partial reduction in RipK3 phosphorylation (Fig. S3
C, D), which did not impact necroptosis (Fig. S3 E).
Inhibition of p38MAPK signiﬁcantly reduced TNFα pro-
duction (Fig S3 F). These results indicate that the phos-
phorylation of RipK1 itself is not required for the
degradation of RipK1.
RipK3-inhibitor GSK84336 that completely blocked the
phosphorylation of RipK3 (Fig. 3b) and necroptosis
(Fig. 3c–g), did not prevent the loss of RipK1 or Casp-8
(Fig. 3b). RipK1 inhibitor (Nec-1) and RipK3 inhibitor
(GSK872) showed similar inhibition of necroptosis as
measured by MTT (Fig. 3c), CCK8 (Fig. 3d) assay, Zombie
yellow staining for dead cells (Fig. 3e, f) and PI/Hoechst
staining (Fig. 3g). Interestingly, GSK843 partially restored
the levels of cIAP1/2 (Fig. 3b), similar to what was
observed with MLKL-deﬁcient cells (Fig. 2g). Similar
results were observed with another RipK3 inhibitor
(GSK872), which resulted in rescue of cIAP1/2, but not
Casp-8 or RipK1 levels (Fig. S3 G, H).
Nec-1, when added at 3 h post-LPS/zVAD treatment
was unable to block RipK1 degradation or death (Fig. 3h,
i). We performed co-immunoprecipitation with an anti-
Fig. 2 TRIF and RipK3 promotes the degradation of necrosomal proteins. a WT and RipK1K45A mutant macrophages were treated with LPS+
zVAD. Expression of various proteins was evaluated by western blotting of cell extracts at different time intervals post-stimulation. b Cell viability of
WT and RipK1K45A macrophages was evaluated by MTT assay at 24 h post stimulation. c, d WT, TRIF−/−, and MyD88−/− macrophages were treated
with LPS+ zVAD and at various time intervals cell extracts were collected and examined by western blotting (c). Cell viability was measured by MTT
assay at 24 h post stimulation of cells with LPS+ zVAD (d). e–g WT, RipK3−/−, and MLKL−/− macrophages were stimulated with LPS+ zVAD and
extracts were collected at various time intervals and tested for the expression of various proteins indicated in the ﬁgure (e, g). Cell viability was
measured by MTT assay at 24 h post stimulation of cells with LPS+ zVAD (f). h, i WT and RipK3−/− macrophages were stimulated with TNFα+ zVAD
and western blot analysis was performed on cell extracts at various time intervals (h). Cell viability was evaluated by MTT assay at 24 h post
stimulation (i). Graphs show the percentage of viable cells ± SEM relative to controls. Each experiment was performed in triplicate and repeated three
times. ***P < 0.001, ****P < 0.0001
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RipK3 antibody and evaluated the impact of inhibition by
Nec-1 vs. GSK872 (Fig. 3j). Addition of Nec-1 completely
blocked the association of RipK1, Casp-8, FADD, and
MLKL with RipK3 in the necrosome. In contrast, addition
of the RipK3-speciﬁc inhibitor (GSK872) blocked only the
RipK3–MLKL interaction (Fig. 3j). Thus, RipK1–RipK3,
but not RipK3–MLKL interaction is necessary for
necrosomal degradation. Overall the results suggest the
existence of two stages of necrosome signaling, an early
necrosome consisting of RipK1, RipK3, Casp-8, FADD
(and possibly other components), and a late necrosome
complex that includes MLKL and is dependent on RipK3-
kinase activity.
Degradation of necrosome impairs cell death and cytokine
expression
We treated cells with LPS+ zVAD to induce necrosome
signaling, but blocked cell death using Nec-1 or GSK872.
Since Nec-1 and GSK872 have opposite impact on
necrosome degradation (Fig. 3a, b), we could speciﬁcally
disentangle the impact of necrosome degradation on
susceptibility to necroptosis and impact on cytokine
Fig. 3 RipK1–RipK3 interaction promotes the degradation of RipK1. a–d WT macrophages were stimulated with LPS+ zVAD in the presence or
absence of Nec-1 (30 μM) (a, c, d) or GSK843/872 (3 μM) (b). Cell lysates were collected at varying time intervals and examined by western blotting (a,
b). Cell viability of macrophages was examined by MTT (c), CCK8 (d) assay, Zombie yellow staining (e, f), and at 24 h post stimulation, or by staining
cells with PI/Hoechst (g) at 6 h post stimulation. h, i Macrophages were treated with LPS+ zVAD. Nec-1 was added immediately, or at various time
intervals post stimulation with LPS+ zVAD. Cell viability (h) was measured at 24 h by MTT assay, and expression of RipK1 (i) was measured by western
blotting of extracts collected at 10 h post stimulation with LPS+ zVAD. j RipK3 was immune-precipitated in control cells and in cells stimulated with
LPS+ zVAD for 3 h in the absence or presence of Nec-1 or GSK872. Expression of various proteins in the immune-precipitates and cell lysates were
examined by western blotting. Graphs show the percentage of viable cells ±SEM relative to controls. Each experiment was performed in triplicate
and repeated three times. ****P < 0.0001
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expression. Primary stimulation of macrophages for 24 h
with LPS+ zVAD and Nec-1 or GSK resulted in resis-
tance to cell death as expected (Fig. 4a), although only
treatment with RipK3 inhibitor (GSK872) resulted in a
sustained loss of RipK1, Casp-8, cIAP1/2, and FADD
expression (Fig. 4a, b).
We were intrigued to test the properties of macro-
phages with depleted levels of cell death mediators. Cells
that expressed poor levels of necrosomal proteins due to
previous treatment with LPS+ zVAD and RipK3 inhibitor
(GSK872) displayed potent resistance to induction of
necroptosis (Fig. 4c). In contrast, cells previously treated
with LPS, LPS+GSK872, or LPS+ zVAD+Nec-1, which
expressed high levels of necrosomal proteins were highly
susceptible to necroptotic cell death (Fig. 4c). Degradation
of necrosome during primary stimulation (LPS+ zVAD
+GSK872) also resulted in signiﬁcantly reduced expres-
sion of cytokines in response to secondary stimulation
(Fig. 4d). These results reveal that early degradation of the
necrosome is a mechanism of cellular escape from
necroptosis and cytokine expression.
RipK3 interaction promotes K48-ubiquitination of
necrosome components
We tested whether a proteasome inhibitor, Lactacystin,
could rescue the loss of the RipK1/Casp-8 levels. Indeed,
Lactacystin induced substantial rescue of RipK1 levels
(Fig. 5a, b), which corresponded to an increase in the
phosphorylation of RipK3 (Fig. 5a, b). Caspase-8 and
cIAP1/2 were partially rescued by Lactacystin treatment
(Fig. 5a, b). Similar results were obtained with another
proteasome inhibitor, MG341 (Fig. S4 A). Inhibition of
transcription (Actinomycin D), endosomal acidiﬁcation
(Chloroquine) and autophagy (hydroxychloroquine) did
not rescue the levels of RipK1 (Fig. S4 B).
We immunoprecipitated ubiquitinated proteins with
“tandem ubiquitination binding entities” (TUBEs) and
performed western blotting of immune-precipitates. We
Fig. 4 Necrosome degradation results in resistance to cell death and impaired cytokine expression. a–d WT macrophages were stimulated as
described in panel a. Cell death was evaluated by MTT at 24 h post stimulation (a), and western blotting was performed in cell extracts collected at
24 h (b). After primary stimulation (24 h), cells were washed and stimulated with LPS, LPS+ zVAD, or LPS+ zVAD+ GSK872, and cell death was
evaluated after another 24 h by MTT assay (c). Supernatants were collected at 6 h post secondary stimulation with LPS and expression of cytokines
was measured by ELISA (d). Graphs show the percentage of viable cells ± SEM relative to cells treated with LPS in the absence of zVAD. Each
experiment was repeated thrice with triplicate samples. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
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observed that RipK1 was profoundly ubiquitinated fol-
lowing stimulation by LPS+ zVAD, but not by LPS
(Fig. 5c, d). Similar results were observed when cells were
stimulated with TNFα+ zVAD (Fig. S4 C, D). Ubiquiti-
nation of RipK1 following LPS+ zVAD stimulation was
signiﬁcantly reduced in RipK3-deﬁcient macrophages
(Fig. 5e, f). Using K48-ubiquitin speciﬁc antibody to
immuno-precipitate proteins, we observed extensive K48
ubiquitination of RipK1 and Caspase-8 following necro-
some activation, which was highly reduced in RipK3-
deﬁcient macrophages (Fig. 5g, h). These results show that
association of RipK1 and RipK3 in the early necrosome
leads to ubiquitination of necrosome components and
drives degradation of interacting proteins.
IAPs do not promote the maintenance of RipK1 during
necrosome signaling
Since cIAPs promote K63-ubiquitination of RipK137, we
evaluated the role of cIAPs in necrosome degradation.
The loss of RipK1 during necrosome signaling remained
unperturbed in cIAP1- or cIAP2-deﬁcient macrophages
(Fig. 6a, b). Necroptosis of macrophages was also not
signiﬁcantly modulated in cIAP1/2-deﬁcient cells
(Fig. 6c). Similarly, the loss of RipK1 or necroptosis was
also not inﬂuenced by the deﬁciency of XIAP (Fig. 6d, e).
We also pre-treated macrophages for 1 h with the SMAC
mimetic Birinapant (BP) which induces rapid degradation
of both cIAPs38,39. Treatment of macrophages with BP
followed by LPS+ zVAD resulted in loss of both cIAPs
Fig. 5 RipK1 is degraded through a proteosomal mechanism. a Macrophages were treated with LPS (100 ng/ml)+ zVAD (50 μM) in the presence
or absence of Lactacystin (10 μg/ml). At various time intervals, cell lysates were collected and examined by western blotting. b Densitometric analysis
of RipK1, pRipK3, Caspase-8, and cIAP1/2. c, d WT macrophages were treated with MG132 (10 μM) and LPS (100 ng/ml) or LPS+ zVAD (50 μM) for
varying time intervals. Lysates were collected and incubated with TUBEs for 16 h at 4 °C as described in Methods. Immuno-precipitates (c) and the
corresponding lysates (d) were examined by western blotting for ubiquitinated proteins. e, f WT and RipK3−/− macrophages were treated with
MG132 (10 μM), LPS (100 ng/ml), and zVAD (50 μM) for varying time intervals as shown. Cells were lysed and immuno-precipitation was then
performed using TUBEs as described in Methods. Immuno-precipitates (e) and lysates (f) were examined by western blotting. g, h WT and RipK3−/−
macrophages were treated with MG132 (10 μM), LPS (100 ng/ml), and zVAD (50 μM) for varying time intervals as shown. Cells were lysed and
immuno-precipitation was then performed using magnetic beads coupled with antibodies targeting K-48. Immuno-precipitates (g) and lysates (h)
were examined by western blotting. Each experiment was repeated thrice
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but did not affect the degradation of RipK1 (Fig. 6f).
Induction of necroptosis by BP+ zVAD treatment also
resulted in degradation of RipK1 (Fig. 6g, h).
A20 and CYLD do not impact the degradation of RipK1
during necrosome signaling
In ﬁbroblasts CYLD and A20 have been shown to edit
the ubiquitination of RipK140,41. We observed that the
expression of CYLD was increased during necrosome
signaling (Figs. 1k and 6i, and Fig. S5 A). CYLD and A20
were phosphorylated during necrosome signaling (Fig. 6j).
Phosphorylation of CYLD has been reported to inhibit its
deubiquitinase (DUB) activity42–44. We performed CYLD
and A20 knock-down separately or in combination and
evaluated the impact on RipK1 degradation. Rather than
inhibiting RipK1 degradation, knock-down of CYLD and/
or A20 appeared to enhance the degradation of RipK1
(Fig. 6k–m and Fig. S5 C, D), suggesting that CYLD and
A20 promote maintenance of RipK1. Similarly, CYLD-
deﬁcient macrophages had little change in degradation of
RipK1, although phosphorylation of RipK3 and necrop-
tosis was signiﬁcantly lower relative to WT macrophages
(Fig. 6n, o). Inhibition of the linear ubiquitin chain
assembly complex (LUBAC) by gliotoxin45 also did not
Fig. 6 cIAPs, CYLD, and A20 do not mediate the degradation of RipK1. a–e Macrophages from WT, cIAP1−/−, cIAP2−/−, and XIAP−/− mice were
treated for varying time intervals with LPS+ zVAD. Lysates were collected and RipK1 expression was examined by western blotting (a, b, e). Cell
viability of WT, cIAP1−/−, cIAP2−/−, and XIAP−/− macrophages stimulated with LPS+ zVAD was measured at 24 h by MTT assay (c, d). WT
macrophages were stimulated with LPS+ zVAD in the presence or absence of the SMAC mimetic BP (10 μM), and the expression of RipK1 and cIAP1/
2 was measured by western blotting of cell extracts at various time intervals (f). Necrosome signaling was induced in WT macrophages by treatment
with BP+ zVAD, and the expression of RipK1, RipK3, and cIAP1/2 was evaluated by western blotting of cell extracts at various time intervals (g). Cell
viability was evaluated by MTT assay at 24 h post stimulation with BP+ zVAD (h). WT macrophages were stimulated with LPS or LPS+ zVAD and
extracts were collected at various time intervals and tested for the expression of A20 and CYLD (i, j). Lambda phosphatase (500 units) was added to
some lysates as described in the Methods section before performing western blotting (j). WT macrophages were transfected with siRNA against CYLD
(15 pmol) (k) or A20 (15 pmol) (l) for 24 h. Cells were then treated with LPS+ zVAD for different time intervals and lysates were collected to measure
RipK1, RipK3, CYLD, and A20 expression by western blotting (k, l). WT macrophages were also transfected with siRNA against both CYLD and A20 for
24 h followed by evaluation of the impact on RipK1, RipK3, A20, CYLD expression at various time intervals following LPS+ zVAD treatment (m).
Macrophages from WT, CYLD−/−, mice were stimulated with LPS+ zVAD for various time intervals (n, o). Expression of RipK1, RipK3, and CYLD was
evaluated by performing western blotting of cell extracts (n). Cell viability was measured at 24 h post stimulation by MTT assay (o). Graphs show the
percentage of viable cells ±SEM relative to controls. Each experiment was repeated three times. ****P < 0.0001
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have any impact on the degradation of RipK1 or
necroptosis (Fig. S5 F, G).
Triad3a promotes necrosome degradation and regulates
cell death and cytokine production
Stimulation of cells with LPS/zVAD initiated cell death
without any evidence of RipK1 degradation for the ﬁrst
few hours (Fig. S6 A, B). There was a deceleration in the
magnitude of cell death between 3 and 8 h that correlated
with a precipitous decrease in necrosomal proteins, sug-
gesting that the loss of necrosomal proteins may act as a
regulatory mechanism to limit cell death. Triad3a is an E3
ubiquitin ligase that interacts with TLRs46, TRIF/RipK147
and regulates TLR signaling46. Since necrosome signaling
and degradation was inhibited in TRIF−/− macrophages
(Fig. 2c, d), we evaluated whether Triad3a impacts the
degradation of RipK1 during necrosome signaling. Knock-
down of Triad3a by siRNA resulted in reduction in the
degradation of RipK1, FADD, and Caspase-8 (Fig. 7a–c),
indicating that Triad3a promotes the degradation of these
proteins during necrosome signaling. Knock-down of
Triad3a did not have a signiﬁcant impact on the degra-
dation of cIAP1/2 (Fig. 7a, b). In the absence of any high-
quality western blot antibody that could speciﬁcally detect
mouse Triad3a, we tested the efﬁciency of Triad3a knock-
down by qRT-PCR, which showed substantial reduction
in Triad3a levels (Fig. 7c). Stimulation of cells with LPS+
zVAD had a marginal impact on cell death at earlier time
periods (Fig. 7d, e), knock-down of Triad3a resulted in
slightly enhanced cell death (Fig. 7e). Triad3a knock-
down resulted in substantial increase in the expression of
inﬂammatory cytokines following necrosome signaling
(Fig. 7f). Overall, these results indicate a model wherein
recruitment of RipK3 to the early necrosome leads to
Triad3a-dependent K48 ubiquitination of RipK1 and
other necosome components as an auto-regulatory
mechanism that limits both cell death and inﬂammatory
cytokine production.
Fig. 7 Triad3a promotes the degradation of necrosome and regulates necroptosis and cytokine expression. a–e WT macrophages were
transfected with siRNA against Triad3a (50, 100, or 200 pmol) for 24 h. Control cells were transfected with scrambled siRNA (100 pmol). Cells were
then treated with LPS+ zVAD for different time intervals and lysates collected for western blotting (a). Densitometric analysis of representative
western blots transfected with 100 pM siRNA was performed (b). Expression of Triad3a was evaluated at 24 h post transfection by qRT-PCR (c). WT
macrophges were treated with LPS (1 ng/ml)+ zVAD (50 μM), and the impact on cell death (MTT assay) and RipK1-expression (western blotting)
evaluated (d). Primary macrophages were transfected with control or Triad3a siRNA for 24 h, and cells were washed next day and cell death was
evaluated at various time intervals post stimulation of cells with LPS (1 ng/ml)+ zVAD (50 μM) by MTT assay (e). Macrophages were transfected with
siRNA against Triad3a as mentioned above. At 24 h, cells were washed and stimulated with LPS (100 ng/ml)+ zVAD (50 μM). Cytokines were
measured in cell supernatants by ELISA (f). Graphs show the percentage of viable cells ±SEM relative to cells treated with LPS in the absence of zVAD.
Each experiment was repeated thrice with triplicate samples. *P < 0.05, **P < 0.01
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Discussion
Since macrophages promote inﬂammatory responses in
various tissues, and necrosome signaling leads to exacer-
bation of inﬂammatory responses13,48,49, understanding
the mechanisms of regulation of necrosome signaling in
macrophages is crucial. The mechanisms through which
RipK1 and RipK3 are phosphorylated during necrosome
signaling are unclear14,50. TLR signaling via TRIF has been
shown to promote phosphorylation of RipK1 in macro-
phages51, however, our results indicate that TRIF-
deﬁcient macrophages had no impairment in phosphor-
ylation of RipK1. Inhibition of RipK1 by Nec-150 also did
not abolish the phosphorylation of RipK1. Furthermore,
RipK1K45A kinase-inactive macrophages also had no
impairment in phosphorylation of RipK1, supporting a
view that RipK1 does not auto-phosphorylate itself. IKK
complex has been previously shown to phosphorylate
RipK152. MK2, the downstream target of p38-MAPK was
shown to mediate an inhibitory phosphorylation on
RipK153. These results support a complex model of RipK1
phosphorylation, wherein multiple kinases can phos-
phorylate RipK1 at multiple sites which can both inhibit
and activate necroptotic cell death52,54.
Downstream of RipK1, we and others have previously
shown that TRIF signaling is necessary for phosphoryla-
tion of RipK3 in macrophages30,51. Interestingly, here we
observe that Nec-1 inhibited the interaction of RipK1 and
RipK3, and blocked the phosphorylation of RipK3, leading
to inhibition of necroptosis and rescue of degradation of
various necrosomal proteins. While previous results have
been interpreted to indicate that RipK1 can phosphorylate
RipK3, our results support a view that Nec-1 blocks
RipK1–RipK3 interaction and does not necessarily impact
on kinase function. More recently, convincing evidence
has emerged to show that RipK3 dimerization leads to
auto-phosphorylation, which is key for downstream acti-
vation of MLKL55,56. We add here a curious observation
that the phosphorylation of RipK3 is abrogated in MLKL-
deﬁcient macrophages, suggesting that RipK3-MLKL
platform may facilitate RipK1-mediated phosphorylation
or auto-phosphorylation of RipK3.
Our results indicate that while the kinase function of
RipK3 is necessary to activate necroptosis, interaction
with RipK3 leads to the degradation of RipK1 and other
necrosomal proteins. This represents a complex model
wherein RipK3 appears to have contrasting functions. Our
results suggest that the formation of an early necrosome
platform that initiates a decision between degradation via
K48-ubiquitination or cell death via RipK3 kinase activity
and MLKL recruitment.
Several ubiquitin ligases have been shown to ubiquiti-
nate RipK1 in TNF-R complex-I, including cIAPs, TRAF2,
and LUBAC. All of these ubiquitinations in the complex I
(M1- or K63-ubiquitin) appear to promote
RipK1 signaling, not degradation57. Consistent with this,
our results indicate that treatment of cells with TNFα or
LPS alone does not induce RipK1 degradation. Rather, we
ﬁnd that RipK1 degradation only occurs following asso-
ciation with RipK3, and is impacted by Triad3a. Inter-
estingly, Triad3a has been shown to cause degradation
and regulation of TLR signaling, including RipK146,47.
Due to the lack of availability of a suitable antibody, we
have been unable to conﬁrm whether RipK3 directly
recruits Triad3a to the necrosome complex.
Various DUBs such as A20 and CYLD remove the
ubiquitination chains on RipK1 as the cells transition
toward the necrosome signaling platform58,59. Our results
show that the expression and phosphorylation of CYLD
increased during necrosome signaling. Interestingly,
phosphorylation of CYLD has been shown to inhibit its
DUB activity42–44.
Casp-860,61, cIAPs38, and Cathepsins62 regulate
necroptosis in macrophages. Here we have introduced a
new mechanism of self-regulation built into necroptotic
signaling. Similar to the inactivating timer mechanism
identiﬁed in the apoptosome63, we reveal here that
recruitment of RipK3 to the necrosome initiates a com-
petition between necrosomal degradation and necrosomal
maturation. This would suggest that the rate of RipK3
kinase activation and MLKL recruitment determine the
proportion of necroptotic death that occurs. By applying
small molecule inhibitors of RipK3, we were able to pre-
vent activation of the late necrosome, resulting in cells
with degraded necrosomal machinery and resistance to
subsequent necroptotic challenge.
RipK119,33 and RipK313,17,30 promote inﬂammatory
responses, and it is not clear whether this is related to the
role of these proteins outside the necrosome complex64,65.
In contrast to apoptosis, which is considered to be
immunologically silent or immune-suppressive66, the
disruption of the cellular membrane and release of
DAMPs during necroptosis is expected to promote
inﬂammatory responses67. Our data indicate that protea-
somal degradation of RipK1 and other early necrosome
components acts to destabilize death inducing complexes
and prevent the completion of the necroptosis program. It
is conceivable that this could result in a pool of cells that
survive cell death induction and maintain key
functionality.
Methods
Mice
C57BL6/J (Jax #000664), TRIF−/− (Jax #005037),
Myd88−/− (Jax #009088), and TNFR1/2−/− (Jax #003243)
were obtained from Jackson Labs (Bar Harbor, USA).
RipK3−/− were a kind gift of Dr. Vishva Dixit (Genentech,
San Francisco, CA, USA); RipK1K45A mice and wild type
litter mates were a kind gift of Dr. Peter J. Gough
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(GlaxoSmithKline, Collegeville, USA); MLKL−/− bone
marrow samples were received from Dr. Emad Alnemri
(Thomas Jefferson University, Philadelphia, USA).
CYLD−/− mice were as previously described68. Experi-
ments were performed in accordance with the Canadian
Council on Animal Care guidelines and the Ethics Board
and/or the Animal Care Committee at University of
Ottawa.
Reagents
Pan-caspase inhibitor, z-VAD-fmk (#A1902) was
obtained from ApexBio (Houston, USA). Lactacystin
(L6785), MG132 (C2211), cyclohexamide (C4859), hydro-
xychloroquine (H0915), and ultrapure LPS (E. coli 0111:B4,
L3024) were obtained from Sigma-Aldrich (Oakville,
Canada). Necroatatin-1 (9037) was obtained from Sigma
Chem Co. (Oakville, Canada). M-CSF (416-ML) and TNFα
(410-MT) were obtained from R&D (Minneapolis, USA).
Birinapant (S7015) was obtained from Selleckchem
(Houston, USA). GSK843 and GSK'872 (AOB4898,
AOB488) were obtained from Aobious (Gloucester, USA).
Caspase-8 Inhibitor, z-IETD-FMK (064-20C) was obtained
from BioVision (San Francisco, USA). P38 inhibitor (5633S)
was obtained from Cell Signaling (Danvers, USA). Alkaline
Phosphatase, Calf Intestinal (CIP) (M0290, NEB). Protease
inhibitors (04693132001) were obtained from Roche
Applied Science (Laval, Canada). PR-619 (SI9619), 1,10-
phenanthroline (SI9649) and GST-tagged tandem
ubiquitin-binding entities (TUBE) (UM102) were obtained
from LifeSensors (Malvern, USA). Actinomycin-D
(0219452505) was obtained from MP Biomedicals (Solon,
USA). Necrostatin-1s (cat# 504297) and MG341 (Bortezo-
mib) (cat# 504314) were obtained from Calbiochem (San
Diego, CA, USA). Zombie Yellow™ Fixable Viability Kit cat#
423103, Biolegend (San Diego, USA).
Generation of macrophages
Primary bone marrow-derived macrophages (BMDMs)
were differentiated in the presence of 5 ng/ml of M-CSF
for 6 days at 37 °C in R8 media (RPMI, 8% fetal bovine
serum, 50 µM β-mercaptoethanol and 50 ng/ml
gentamycin)30.
Cell culture and viability assay
BMDMs were stimulated in either 24- or 96-well tissue
culture plates with LPS (100 ng/ml) or TNF-α (1000 U/
ml), in the presence of pan-caspase inhibitor zVAD (50
μM). In some experiments, BMDM were co-treated with
various inhibitors and agonists 30 min before stimulation
and left for a couple of hours before assaying the cell
viability or collecting protein lysate. Cell viability was
measured using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyltetrazolium bromide (MTT) assay. The MTT reagent
was diluted with R8 media at a ﬁnal concentration 0.5 mg/
ml and incubated at 37 °C. After 2 h, 5 mM HCl isopropyl
alcohol were added to solubilize MTT crystals and
absorbance was measured at a wavelength of 570 nm with
a reference wavelength of 650 nm on a Molecular Devices
FilterMax plate reader. Cell Counting Kit-8 (CCK-8) was
used and 10 μl was added to each well and incubated at
37 °C for 2–4 h. After incubation the absorbance was
measured at 450 nm using Molecular Devices FilterMax
plate reader. CCK-8 (cat# CK04-01) was obtained from
Dojindo Molecular Technologies (Rockville, USA).
Flow cytometry
Zombie Yellow™ (BioLegend, San Diego, CA) was used
to assess cell viability. Using BPS buffer, 24 h after treating
the cells in a 96-well plate with various treatments, the
seeded cells were washed twice. Without detaching the
cells, 50 μl of diluted Zombie Yellow™ solution (1:100 in
PBS) was added into each well and the plates were incu-
bated at room temperature, in the dark, for 15–30 min
before washing with 100 μl FACS buffer (PBS, 1% BSA, 1
mM EDTA) once. Then, samples were ﬁxed by using 1%
paraformaldehyde and analyzed with a LSR Fortessa cell
analyzer and FACSDiva software (Becton Dickinson). The
data were analyzed with FlowJo software.
Quantitative RT-PCR
Total RNA was isolated using TRIzol reagent (Life
Technologies). Isolated RNA was reverse transcribed into
cDNA in a 20-μl reaction volume using SuperScript III
Reverse Transcriptase (Invitrogen,18080– 044) as follows:
1 μg of RNA template was added to 0.5 μl of oligo(dT) (50
μM), 0.5 μl of random primers (50–250 ng), 4 μl of 5×
First Strand buffer, 1 μl of DTT (0.1M), 1 μl of dNTP (10
mM), 1 μl of RNase OUT (40 units/μl), and 1 μl of
SuperScript III (200 units/μl). After cDNA synthesis, 2 μl
of cDNA was analyzed using the SYBR Green (Life
Technologies) fast method performed on an Applied
Biosystems 7500 quantitative RT-PCR system. The pri-
mers used were as follows: Actin (forward) 5′-GAT
CAAGATCATTGCTCCTCCTG-3′, (reverse) 5′-AGGG
TGTAAAACGCAGCTCA-3′; RipK1 (forward) 5′-GGCC
AACATTTCTTGGCATTGA-3′, (reverse) 5′-CTGCAG
CACTGGGCTTTGAT-3′; Caspase-8 (forward) 5′-TGCC
CAGATTTCTCCCTACA-3′, (reverse) 5′-AAGCAGGCT
CAAGTCATCTTCC-3′. Triad3a (forward) 5′-ACAGA
TGATCACCATGTTTGGTT-3′, (reverse) 5′-CATCCA
TTCCTTTCCCCGGT-3′.
RNA interference
The smart pool ON-TARGETplus siRNA against
CYLD, A20, and TRIAD3A were purchased from Dhar-
macon (GE Healthcare, USA). BMDMs were transfected
with siRNA using Lipofectamine® RNAiMAX Transfec-
tion Reagent (13778030, Invitrogen) according to the
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manufacturer’s instructions. After 24 h, the transfected
cells were used for time course experiments. Sequence of
the siRNAs is provided in the supplemental section.
Western blotting
Cells were stimulated as indicated and lysed in SDS lysis
buffer with 1% β-mercaptoethanol and boiled immedi-
ately at 95 °C for 5 min. Lysates were separated by 10% or
8% SDS-PAGE and transferred to PVDF membrane.
Immunoblot analysis was performed using the following
antibodies: mouse anti-RipK1 (610458, BD Biosciences,
Mississauga, Canada), rabbit anti-RipK3 (2283, ProSci
Inc., Poway, USA), mouse anti-actin (47778, Santa Cruz
Biotechnology, Dallas, USA), rabbit anti-STAT1 (9172,
Cell Signaling), rat anti-caspase-8 (1G12, Enzo), rabbit
anti-CIAPs (CY-P1041, Cyclex), rat anti-MLKL mono-
clonal (MABC604, EMD Millipore), rabbit anti-CYLD
(8462, Cell Signaling), rabbit anti-A20 (5630, Cell Sig-
naling, Danvers, USA), mouse anti-FADD (1F7, Enzo,
Farmingdale, USA) and mouse anti-αTublin (5286, Santa
Cruz Biotechnology, Dallas, USA). Rabbit anti-PP2A B
subunit (100C1) was obtained from Cell Signaling Inc. In
some cases, whole cell lysates were prepared in RIPA-
EDTA free buffer supplemented with protease inhibitor
and 50 Units of calf intestinal phosphatase (CIP) was used
to dephosphorylate the total protein in 1× CutSmart NEB
buffer for 50min at 37 °C. SDS lysis buffer was added to
the treated samples and boiled for 5 min at 95 °C followed
by standard western blot protocol.
Immunoprecipitations
Cell lysates were immunoprecipitated with Dynabeads
co-immunoprecipitation kit (Invitrogen, Life Technolo-
gies, Burlington, Canada) with the following antibodies:
rabbit anti-RipK3 (2283, ProSci Inc., Poway, USA), rabbit
anti-K48 ubiquitin (Apu2, Millipore, USA), and rabbit
anti-K63 ubiquitin (Apu3, Millipore, Burlington, Canada).
Bound proteins were eluted and subsequently analyzed by
western blot standard protocol. The densitometric
quantiﬁcation of western blot signals was performed using
ImageJ 1.48 software (Maryland, USA).
For immune-precipitation with tandem ubiquitin-
binding entities (TUBES), BMDMs were treated with
proteasome inhibitor MG132 (5 μg/ml) before stimulation
with LPS/zVAD or TNF/zVAD. Cells were washed with
ice-cold 1× PB and lysed in buffer contains 50mM Tris-
HCL pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 10%
glycerol, protease inhibitor, phosphatase inhibitor, 20 μM
deubiquitinase inhibitor PR-619 and 1× 1,10-phenan-
throline. The lysates were sonicated for 10 s 3 times and
then centrifuged at 14,000 × g for 30 min at 4 °C to pellet
cell debris. The clariﬁed lysate were then incubated with
equilibrated Agarose-TUBEs for 16–24 h at 4 °C on a
rocker platform. After incubation, the beads were
collected by low speed centrifugation 5000 × g for 5 min at
4 °C. The unbound fractions were saved at −20 °C and the
beads were washed 3 times with ice-cold TBS-T washing
buffer that contains 20mM Tris-HCL pH 8, 150mM
NaCl and 0.1% Tween-20. The resin was re-suspended in
40 μl of 2× SDS lysis buffer and boiled for 5 min at 95 °C
then centrifuged at 13,000 × g for 5 min at room tem-
perature. The eluent was analyzed by standard western
blot protocol.
Cytokine analysis
Supernatants were collected from 24-well plates and the
expression of cytokines was assessed using the BD optEIA
ELISA kit (eBioscience, CA, USA) according to the
manufacturer’s instructions. The absorbance was read at
450–570 nm on a FilterMax F5 Multimode microplate
reader (Molecular Devices).
Statistical analyses
All graphs show the average result taken from at least
three independent experiments. Error bars show the
standard error of the mean, and statistical signiﬁcance
between groups were determined by using Student’s t-test
using Graphpad Prism 6.07 software package (La Jolla,
California, USA).
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